Skip to main content

Intellectual Property Rights and U.S.-Japan Competition in Biotechnology Report of a Workshop (1991) / Chapter Skim
Currently Skimming:

1. Introduction
Pages 1-4

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 1...
... commercial biotechnology fear that biotechnology may go the way of semiconductors, with Japanese and other foreign-based firms reaping most of the economic benefits generated by a high technology industry in which the breakthroughs and pioneering commercialization largely occurred within the United States. Along with other factors, they point to differences in the treatment of intellectual property rights (IPR)
Read the entire page →
From page 2...
... A recent report by the President's Council on Competitiveness asserts present American leadership in commercial biotechnology, and also sums up the importance and promise of this relatively new field: "In the long run, because of the pervasive role of biologically produced substances in everyday life, biotechnology has the potential to surpass the computer industry in size and scope."3 The report also underscores the importance of intellectual property nghts, stating that 2For a discussion of objections to the Japanese patent system made by many Americans, see Stephanie Epstein and James Matthew Jones, Intellectual Property at a Crossroads: Global Piracy and International Competitiveness (Arlington, Va.: Congressional Economic Leadership Institute, 1990)
Read the entire page →
From page 3...
... The focus here will be on the impact of intellectual property rights on the competitive strategies and fortunes of Japanese and American commercial biotechnology firms. It is not inevitable that the United States will dominate this industry in the next century.
Read the entire page →
From page 4...
... Hubert Schoemaker, Chairman and CEO of Centocor, the workshop was designed to provide a forum to examine the experiences of U.S. firms with the IPR environment for biotechnology in Japan, to discuss the implications of the growing presence of Japanese firms in the United States, and to evaluate future prospects and policy implications for the United States.
Read the entire page →

Key Terms

  • japanese firms
  • commercial biotechnology
  • international patent
  • japanese biotechnology
  • biotechnology companies

  • japanese ipr
  • biotechnology firms
  • japanese patent
  • japanese representation
  • attorneys assert

  • foreign patent
  • eventually reap
  • financially weak
  • american biotechnology
  • future impact

  • marketing products
  • biologically produced
  • computer industry
  • firms reaping
  • balance concerns

  • commonly heard
  • patent attorneys
  • playing field
  • third generation
  • everyday life

  • insufficient attention
  • japanese rules
  • global marketplace
  • conflicting goals
  • obtaining effective


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.